Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility: Evidence from case-control studies
- PMID: 30557992
- PMCID: PMC6320213
- DOI: 10.1097/MD.0000000000013386
Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility: Evidence from case-control studies
Abstract
Objective: Several published studies have investigated the association between the -308G/A (rs1800629) polymorphism in the tumor necrosis factor-α (TNF-α) gene and the risk of dilated cardiomyopathy (DCM). However, the TNF-α gene polymorphism has a controversial role in the pathogenesis of DCM among different populations. In the present study, a meta-analysis was performed to resolve this inconsistency.
Methods: Potentially eligible papers reporting an association between the TNF-α rs1800629 polymorphism and DCM susceptibility were searched in 4 databases including PubMed, EMBASE, Chinese Biomedical Database (CBM), and the Cochrane Library up to April 1, 2018. The odds ratio (OR) with its 95% confidence interval (CI) was used to estimate the strength of the associations. Subgroup analysis based on the ethnicity, studies with or without ischemic and valvular DCM was conducted. Publication bias detection was conducted using Begg test.
Results: Nine papers detailing case-control studies were included, reporting a total of 1339 DCM cases and 1677 healthy controls. The meta-analysis results indicated that TNF-α rs1800629 was associated with increased DCM susceptibility in the populations studied under the heterozygous model (AG vs GG: OR = 1.91, 95% CI = 1.05-3.50, P = .035) and dominant model (AG + AA vs GG: OR = 1.87, 95% CI = 1.01-3.45, P = .046). In the subgroup analysis for ethnicity, rs1800629 polymorphism was significantly associated with the susceptibility of DCM for Asians under the 5 models (A vs G: OR = 2.87, 95% CI = 1.56-5.30, P = .001; AA vs GG: OR = 3.95, 95% CI = 1.13-13.82, P = 0.031; AG vs GG: OR = 3.8, 95% CI = 1.57-9.19, P = .003; AA vs GG + AG: OR = 2.51, 95% CI = 1.41-4.49, P = .002; AG + AA vs GG: OR = 3.77, 95% CI = 1.54-9.20, P = .004).
Conclusion: There may be a moderate association between TNF-α rs1800629 polymorphism and DCM susceptibility in the whole populations studied; however, TNF-α rs1800629 polymorphism was significantly associated with the susceptibility of DCM for Asians, which indicates that such associations may be different between ethnicities.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures




Similar articles
-
Association between tumor necrosis factor-α-308G/A gene polymorphism and susceptibility to pre-eclampsia: An updated meta-analysis.Cytokine. 2018 Nov;111:278-286. doi: 10.1016/j.cyto.2018.09.002. Epub 2018 Sep 21. Cytokine. 2018. PMID: 30245306
-
Tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical lesions: a meta-analysis.PLoS One. 2013 Aug 27;8(8):e69201. doi: 10.1371/journal.pone.0069201. eCollection 2013. PLoS One. 2013. PMID: 24015171 Free PMC article.
-
Tumor Necrosis Factor-α Gene Polymorphism (G-308A) and Dilated Cardiomyopathy.Int Heart J. 2019 May 30;60(3):656-664. doi: 10.1536/ihj.17-293. Epub 2019 Apr 25. Int Heart J. 2019. PMID: 31019168
-
Association of TNF-α -308G>A Polymorphism with Susceptibility to Cervical Cancer and Breast Cancer - a Systematic Review and Meta-analysis.Klin Onkol. 2019 Spring;32(3):170-180. doi: 10.14735/amko2019170. Klin Onkol. 2019. PMID: 31216848 English.
-
ASSOCIATION OF TNF- α-308G>A POLYMORPHISM WITH SUSCEPTIBILITY TO CELIAC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.Arq Gastroenterol. 2019 May 20;56(1):88-94. doi: 10.1590/S0004-2803.201900000-20. Arq Gastroenterol. 2019. PMID: 31141070
Cited by
-
Genetic association between the lncRNA ANRIL rs10757272 polymorphism and intracranial aneurysm susceptibility in Asians.Neurosurg Rev. 2022 Dec 13;46(1):15. doi: 10.1007/s10143-022-01927-9. Neurosurg Rev. 2022. PMID: 36512102
-
Inflammation-Related Biomarkers Are Associated with Heart Failure Severity and Poor Clinical Outcomes in Patients with Non-Ischemic Dilated Cardiomyopathy.Life (Basel). 2021 Sep 24;11(10):1006. doi: 10.3390/life11101006. Life (Basel). 2021. PMID: 34685378 Free PMC article.
-
Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.Int J Mol Sci. 2021 May 26;22(11):5688. doi: 10.3390/ijms22115688. Int J Mol Sci. 2021. PMID: 34073616 Free PMC article. Review.
-
Exploring the diagnostic and prognostic value of the C-reactive protein/lymphocyte ratio for dilated cardiomyopathy based on a real-world study.Sci Rep. 2023 Nov 2;13(1):18889. doi: 10.1038/s41598-023-46338-y. Sci Rep. 2023. PMID: 37919409 Free PMC article.
References
-
- Bruggink AH, van Oosterhout MF, De Jonge N, et al. TNFalpha in patients with end-stage heart failure on medical therapy or supported by a left ventricular assist device. Transpl Immunol 2008;19:64–8. - PubMed
-
- Tavares PS, Rocon-Albuquerque R, Jr, Leite-Moreira AF. Innate immune receptor activation in viral myocarditis: pathophysiologic implications. Rev Port Cardiol 2010;29:57–78. - PubMed
-
- Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg cardiomyopathy study. Circulation 2003;108:2883–91. - PubMed
-
- Tiret L, Mallet C, Poirier O, et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 2000;35:29–35. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous